First-generation Ad5/35 vector has been used in clinical trials for ex vivo T cell transduction.41, 42 Helper-dependent vectors derived from serotype 5 (HDAd5) have been tested in mice, dogs, and non-human primates for the treatment of diseases, including Apoplipoprotein A (ApoE) deficiency, atherosclerosis, α1 anti-trypsin deficiency, cystic fibrosis, Duchenne muscular dystrophy, glioblastoma, and infectious diseases (for a review, see Rosewell et al.43 Here, APOE is linked to atherosclerosis.